2017-10-23

Immunovia signs major autoimmune biomarker discovery collaboration with Linköping University

Aim to develop next generation of autoimmune diseases diagnostics based on IMMray™ antibody array platform.

LUND, Sweden ― Immunovia announced today the signing of a major research collaboration on discovery of diagnostic biomarkers for autoimmune diseases with the Faculty of Medicine and Health Sciences, Linköping University. The collaboration aims to accelerate the development of a new generation of diagnostic tests based on Immunovia’s leading IMMray™ antibody array platform.

The Linköping collaboration forms the next step in Immunovia’s autoimmune diseases program and additionally extend the scope of providing solutions to clinical unmet needs. It covers 4 of the major diseases within autoimmunity – Rheumatoid Arthritis (RA) with Prof. Thomas Skogh and Assoc. Prof. Alf Kastbom; Primary Sjögren’s Syndrome with Assoc. Prof. Per Eriksson; Systemic Lupus Erythematosus (SLE) with Assoc. Prof. Christopher Sjöwall; Vasculitis with Prof. Mårten Segelmark and Assoc. Prof. Per Eriksson. This complements and strengthens the current collaboration with Lund University (see press release published Sept 7, 2017) by providing access to important biobanks of clinically well documented samples and extensive autoimmune diseases expertize. 

”We are delighted to sign this collaboration with Linköping University and to assemble a group of clinicians with such a broad expertise of different autoimmune diseases. There is a major need for differential diagnostics in this area and we believe IMMray™ platform is particularly suited to develop accurate, rapid and reliable patient diagnostics to enable better patient management. Our IMMray™ SLE-d is already showing promising results with differential diagnosis accuracies above 95%, this encouraged us to extend our autoimmune discovery program to the next level, to address the very attractive autoimmune diseases diagnostic market with innovative solutions to currently unmet needs” said Mats Grahn, CEO, Immunovia.


For more information, please contact: 

Mats Grahn

Chief Executive Officer, CEO, Immunovia

Tel.: +46-70-5320230

Email: mats.grahn@immunovia.com


About Immunovia

Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com)

This information is information that Immunovia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on the date and time as shown above.

Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit www.immunovia.com.